1 / 29

Haemolytic Uraemic Syndrome

Haemolytic Uraemic Syndrome. David V Milford. Paediatric Nephrology for the General Paediatrician 2012 Manchester. Overview. Presentation Diagnosis Management Prognosis and follow-up Atypical HUS. Haemolytic uraemic syndrome. s. in childhood. Syndrome comprising.

ayanna
Download Presentation

Haemolytic Uraemic Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Haemolytic Uraemic Syndrome David V Milford Paediatric Nephrology for the General Paediatrician 2012 Manchester

  2. Overview • Presentation • Diagnosis • Management • Prognosis and follow-up • Atypical HUS

  3. Haemolytic uraemic syndrome s in childhood Syndrome comprising acute renal failure of varying severity microangiopathic anaemia thrombocytopenia of varying severity Multiple aetiologies

  4. BPSU National HUS study 1985-1988 D+ D- reported 282 (94.6%) 16 (5.4%) dialysed 165 (59%) 9 (56%) followed for > 4 259 15 months lone hypertension 3 2 CRF 17 2 78% 13.6% ESRF 0 5 died 15 3 Arch. Dis. Child 1990; 65:716‑721

  5. Arch. Dis. Child 1990; 65:716‑721

  6. Evolution of lab results in HUS – outbreak in an institution

  7. Diagnosis • Diarrhoea (often bloody) • Haematological – microangiopathic haemolytic • anaemia • - thrombocytopenia Fragmented red cells Absence of platelets

  8. Acute Kidney Injury

  9. Shiga toxin producing E.coli (STEC) isolates BAPN/CDC study 1985-88 isolates VTEC O157 HUS 185 60 39 Bloody diarrhoea 48 4 3 Diarrhoea 54 3 1 Controls 46 2 0 Arch. Dis. Child. 1990; 65:722‑727

  10. D+ HUS and EHEC • EHEC colonise cattle • Transmission – contaminated meat, milk, water, fruit, vegetables • Exposure to EHEC → diarrhoea in ≈ 10% children • HUS develops in ≈ 15% of children with EHEC diarrhoea • O157:H7 predominant serotype in the UK • O26:H11, O103:H2, O111:NM, O121:H19, O145:NM

  11. Annual STEC cases in the UK Emerging Infectious Diseases 2005; 11: 590-6

  12. Non-renal complications • Seizures • hyponatraemia • neurotoxicity (STx receptors – neurones, endothelium) • Hypertension • Gut • rectal prolapse • toxic megacolon, perforation, intussception • Cardiomyopathy • Diabetes mellitus

  13. Acute CNS changes 6 months Even in patients with severe CNS involvement on acute imaging studies, prognosis can be favourable for clinical outcome and resolution of pathological imaging findings Pediatr Radiol (2004) 34: 805–810 Clin J Am Soc Nephrol 2010; 5:1218–1228,

  14. Rectal prolapse Air in bowel Late change - stricture

  15. Emerging Infectious Diseases 2005; 11: 590-6

  16. 395 D+ HUS 18 D- HUS Infections in HUS 1997-2001 1 O26 65 329 (83%) O157 +ve culture/serology No infection identified 59 S pneumonae 7 Campylobacter 2 CKD 1 Died 2 (out of 8 cases) Shigella Sonnei 1 S pneumonae 1 Staph aureus 1 Emerging Infectious Diseases 2005; 11: 590-6

  17. Northern German outbreak May-July 2011 • Source: bean sprout farm in Lower Saxony • Sprouted from batch of seeds from Egypt • 3793 cases of diarrhoea – O104:H4 • Delay in symptoms, ingestion → diarrhoea 8 days • 827 (22%) developed HUS, 88% in adults • 53 deaths • 2010 European data • 4000 STEC cases reported, 5.5% developed HUS • O157 (41%), 026 (7%), O103 (2.5%)

  18. Management • Conservative • Monitor fluid balance, sodium, potassium, H+,BP • Furosemide may be useful early • Sodium, protein restriction; high calorie intake • Transfuse with caution • Avoid antibiotics/anti-motility agents/NSAID • Transfer to regional centre • Oliguria + • Fluid overload, need for transfusion, high K • Anuria • Complications of D+ HUS

  19. Prognosis and follow-up • BCH (n=250) 56% required acute dialysis • Prognostic markers • Neutrophils >20 at presentation • Dialysis > 2weeks • Mortality • 5% (BPSU 1985-88) • 1.8% (BPSU 1997-2001) • Long term: HBP, reduced GFR, proteinuria • Variable in studies, probably 20-30% • BCH n=201 19% poor outcome at 5,10,0r 15 yrs

  20. Proteinuria at 1 year and outcome Poor outcome Good outcome J Pediatr 1991; 118:191‑4

  21. Follow-up • Frequently until Hb and creatinine normal • BP, PCr and EMU protein at 1 year after illness • BP, EMU protein, formal GFR, renal USS at 5 years and every 5 years until post pubertal • BP, EMU protein by GP at intervals once discharged • Lifestyle advice • Avoid overweight, high sodium intake • Avoid smoking • Girls need renal function/proteinuria monitoring during pregnancy

  22. Level 1: aetiology advanced 1.i Infection induced (a) Shiga and shiga-like toxin-producing bacteria; enterohaemorrhagic Escherichia coli, Shigella dysenteriae type 1, Citrobacter freundii (b) Streptococcus pneumoniae, neuraminidase and T-antigen exposure 1.ii Disorders of complement regulation (a) Genetic disorders of complement regulation (b) Acquired disorders of complement regulation, e.g. anti-factor H antibody 1.iii von Willebrand proteinase, ADAMTS13, deficiency (a) Genetic disorders of ADAMTS13 (b) Acquired ADAMTS13 deficiency; autoimmune, drug induced 1.iv Defective cobalamin metabolism 1.v Quinine induced Level 2: aetiology unknown 2.i Human immunodeficiency virus (HIV) 2.ii Malignancy, cancer chemotherapy and ionising radiation 2.iii Calcineurin inhibitors and transplantation 2.iv Pregnancy, HELLP syndrome and oral contraceptive pill 2.v Systemic lupus erythematosus and antiphospholipid antibody syndrome 2 vi Glomerulopathy 2.vii Familial, not included in part 1 2.viii Unclassified Typical/diarrhoeal/ D+ HUS Atypical/ non-diarrhoeal/ D- HUS

  23. Alternative complement pathway Johnson, Eur J Pediatr 2008:167;965–971

  24. Non-diarrhoeal HUS • Requires urgent referral to a nephrology centre • Associated with • High risk of death, CKD, hypertension, CNS events, recurrent episodes, familial • Therapies used • Plasmapheresis • Plasma infusion (especially ADAMTS13) • Eculizumab (binds to C5 and blocks C5 convertase) • Liver, liver/kidney transplantation

  25. QUESTIONS?

  26. Glomerular size in HUS patients with proteinuria 3.3-7 years after illness n=7 J Pediatr 1998; 133:220-3

More Related